RECRUITINGOBSERVATIONAL

REtinal Markers In Neuroinflammatory Diseases ("REMIND")

Retinal Markers in Neuroinflammatory Diseases: a Prospective Observational Study

About This Trial

The goal of this observational study, including patients with Multiple Sclerosis, patients with other neuroinflammatory diseases and healthy controls, is to determine the predictive value of retinal markers in predicting disease progression. Participants complete a questionnaire and undergo various non-invasive retinal routine clinical examinations.

Who May Be Eligible (Plain English)

Who May Qualify: 1. All groups: - Age \>18 years old 2. Patients with Multiple Sclerosis: - Diagnosis of Multiple Sclerosis, according to the last revisions of the McDonald Criteria (2017) 3. Patients with other neuroinflammatory diseases: - Diagnosis of Neuromyelitis optica spectrum disorder or Myelin oligodendrocyte glycoprotein antibody disease or other neuroinflammatory disorders other than Multiple Sclerosis Who Should NOT Join This Trial: 1. All groups: - Inability to undergo Optical Coherence Tomography (OCT) and/or retinal vessel imaging (e.g. severe nystagmus that prevents eye fixation on both eyes) - Presence of any ocular pathology that may interfere with the validity of the OCT/retinal vessel analysis (cataracts, glaucoma, history of refractive defects \>6 D etc.). - Pregnancy and Lactation 2. Healthy Controls - History of other neurological conditions: participants with a history of other significant neurological conditions that might interfere with the assessment or interpretation of the signs and symptoms will be excluded (e.g. confirmed Stroke, Acute disseminated encephalomyelitis, Chronic inflammatory Demyelinating Disease, Polyneuropathy, etc.) Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: 1. All groups: * Age \>18 years old 2. Patients with Multiple Sclerosis: * Diagnosis of Multiple Sclerosis, according to the last revisions of the McDonald Criteria (2017) 3. Patients with other neuroinflammatory diseases: * Diagnosis of Neuromyelitis optica spectrum disorder or Myelin oligodendrocyte glycoprotein antibody disease or other neuroinflammatory disorders other than Multiple Sclerosis Exclusion Criteria: 1. All groups: * Inability to undergo Optical Coherence Tomography (OCT) and/or retinal vessel imaging (e.g. severe nystagmus that prevents eye fixation on both eyes) * Presence of any ocular pathology that may interfere with the validity of the OCT/retinal vessel analysis (cataracts, glaucoma, history of refractive defects \>6 D etc.). * Pregnancy and Lactation 2. Healthy Controls * History of other neurological conditions: participants with a history of other significant neurological conditions that might interfere with the assessment or interpretation of the signs and symptoms will be excluded (e.g. confirmed Stroke, Acute disseminated encephalomyelitis, Chronic inflammatory Demyelinating Disease, Polyneuropathy, etc.)

Treatments Being Tested

DIAGNOSTIC_TEST

Optical coherence tomography (OCT)

OCT is used to measure: * peripapillary retinal nerve fiber layer (mean thickness in μm) * ganglion cell-inner plexiform layer (volume in mm\^3 and mean thickness in μm) * other retinal layers (inner nuclear layer, outer plexiform layer, outer nerve layer; volumes in mm\^3 and mean thickness in μm). The "scanner laser ophthalmoscopy"-function of the OCT device is used to continuously record the exact location of each participant's fixation point in relation to their fovea and thereby allows the assessment of the fixation instability. In a subgroup of participants, the "angiography"-module of the OCT device is used to image the retinal blood flow and thereby allows to measure the vascular area density of the superficial retinal capillary plexus and deep retinal capillary plexus.

DIAGNOSTIC_TEST

Static retinal vessel analyzer

Static retinal vessel analyzer is used to determine: * central retinal arteriolar diameter equivalents (in μm) * central retinal venular diameter equivalents (in μm) * arteriolar-to-venular diameter ratio

DIAGNOSTIC_TEST

Dynamic retinal vessel analyzer

In a subgroup of participants, the dynamic retinal vessel analyzer is used to determine the arteriolar ficker light-induced dilatation, venular ficker light-induced dilatation, and Arteriolar constriction, measured in % dilatation in comparison to baseline.

DIAGNOSTIC_TEST

Laser speckle flowgraphy system

In a subgroup of participants, the laser speckle flowgraphy system is used to measure the relative ocular blood flow as expressed in arbitary units of Mean Blur Rate.

OTHER

Questionnaire

All study participants will be asked to fill in a questionnaire with various questions regarding existing eye diseases, other diseases (including vascular diseases/risk factors), and daily physical activity that could influence the results of the retinal examinations. Physical activity will be assessed using an adapted form of the standardized Global Physical Activity Questionnaire.

Locations (1)

University Hospital Basel, Department of Neurology

Basel, Switzerland